Doximity Raises Guidance, But EPS Miss Halts Rally

Doximity (DOCS) reported fiscal 2027 Q1 earnings on Aug 06th, 2026.

The company delivered a revenue beat of $4.87 million against consensus estimates, driven by strong subscription growth. However, Non-GAAP EPS of $0.29 slightly missed expectations by $0.01. Management raised full-year fiscal 2027 revenue guidance to $671M-$681M, reflecting robust AI commercial momentum and Q1 outperformance, despite lowering the adjusted EBITDA range due to tough prior-year comparisons.

Revenue

The total revenue of Doximity increased by 7.3% to $156.62 million in 2027 Q1, up from $145.91 million in 2026 Q1. Subscription revenues reached $146.3 million, representing a 6.1% year-over-year increase and beating analyst estimates of $142.87 million. Other revenues contributed $10.32 million, marking a significant 28.4% jump from the prior year and surpassing the average estimate of $9.04 million.

Earnings/Net Income

Doximity's EPS declined 53.6% to $0.13 in 2027 Q1 from $0.28 in 2026 Q1. Meanwhile, the company's net income declined to $24.32 million in 2027 Q1, down 54.4% from $53.32 million reported in 2026 Q1. The Company has sustained profitability for 6 years over the corresponding fiscal quarter, reflecting stable business performance. The reported Non-GAAP EPS of $0.29 slightly missed consensus, indicating modest earnings pressure despite top-line growth.

Price Action

The stock price of Doximity has edged down 2.59% during the latest trading day, has edged down 2.73% during the most recent full trading week, and has tumbled 9.15% month-to-date.

Post-Earnings Price Action Review

Shares exhibited mixed reactions following the report, initially surging approximately 64% in after-hours trading due to raised full-year revenue guidance, which signaled strong confidence in the AI commercial pipeline. However, the stock subsequently retreated, ending the day down 2.59% and posting a 9.15% month-to-date decline, reflecting investor caution over the significant drop in net income and the slight EPS miss. Despite the short-term volatility, the company maintained a Zacks Rank of #3 (Hold), suggesting potential for performance in line with the broader S&P 500 market in the near term.

CEO Commentary

Jeff Tangney, Co-founder and CEO, highlighted that Doximity achieved revenue growth re-acceleration to $157 million in Q1, up 7% year-over-year, while maintaining best-in-class software margins despite heavy AI investment. He emphasized winning the independent "No Harm" study with the lowest clinical error rates, attributing success to a unique built-in drug reference and 12,000 physician editors. Strategic priorities include leveraging Doximity Ask and AI Search to become the number one most used clinical service, positioning the company as a comprehensive "doctor’s digital assistant" integrating Scribe, telehealth, and decision support. Tangney expressed optimism about the shift from individual AI usage to enterprise-wide adoption driven by privacy and safety concerns, noting strong momentum with health systems like Northwestern and Penn Medicine. He believes this positions Doximity to capture significant long-term value as hospitals prioritize secure, accurate, and private AI solutions.

Guidance

Doximity provided revised financial outlooks reflecting stronger-than-expected Q1 performance and a robust AI commercial pipeline. For the second quarter of fiscal 2027, the company expects revenue between $170 million and $171 million, representing a midpoint growth of approximately 1% year-over-year. Full-year fiscal 2027 revenue guidance was raised by $6 million to a range of $671 million to $681 million, implying 5% growth at the midpoint. Adjusted EBITDA for Q2 is projected at $80.5 million to $81.5 million, maintaining a 48% margin. Full-year adjusted EBITDA is now expected to range from $309 million to $329 million, with a midpoint margin of 47%. Management attributes the upward revision to flow-through from Q1 outperformance and modest incremental revenue raises, while noting that Q2 growth faces tough comparisons against prior year highs.

Additional News

Doximity has been actively engaging with industry stakeholders to expand its clinical utility footprint. Recent developments highlight the company's strategic focus on enterprise-wide AI adoption, securing partnerships with major health systems such as Northwestern and Penn Medicine. These collaborations underscore the growing demand for secure, privacy-focused clinical decision support tools within hospital networks. Additionally, the company continues to leverage its network of 12,000 physician editors to enhance the accuracy and safety of its digital health solutions. This emphasis on clinical integrity and data privacy positions Doximity favorably as healthcare providers seek reliable AI integrations. The company's efforts to transition from individual user adoption to institutional deployment reflect a broader industry trend toward standardized, compliant digital health infrastructure. These strategic moves aim to solidify Doximity's role as a critical digital assistant for physicians, driving long-term value through enhanced clinical workflows and operational efficiency.